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Abstract
The newly established rat strain TGR(mREN2)27 is a mono-
genetic model in hypertension research. Microinjecting the
mouse Ren-2d renin gene caused it to become a stable part of
the genome. The rats are characterized by fulminant hyperten-
sion, low plasma active renin, suppressed kidney renin, high
plasma inactive renin, and high extrarenal transgene expres-
sion, most prominently in the adrenal cortex. Additionally, they
exhibit significantly enhanced excretion of corticosteroids.
Here we demonstrate that part of the plasma renin and most
of the adrenal renin are transgene determined and that the adre-
nal renin is strongly activated. TGR(mREN2)27 adrenal cells
may serve as a new tool to investigate the regulation and pro-
cessing of Ren-2d-derived renin and its significance in hyper-
tension and steroid metabolism.
Adrenal renin in TGR(mREN2)27 is stimulated by 8-
bromo-cAMP (8-Br-cAMP), angiotensin II (ANGII), and cal-
cium. 8-Br-cAMP significantly stimulates active renin and pro-
renin release, as well as Ren-2d mRNA. Interestingly, within
60 min 8-Br-cAMP, ANGII, and calcimycin stimulate active
renin, but not prorenin release. This indicates different intra-
cellular pathways.
An activated adrenal renin-angiotensin system in TGR
(mREN2)27 as well as the lack of negative feedback on renin
secretion by ANGII may be of pathophysiological significance
in this hypertensive model. (J. Clin. Invest. 1993. 742-747.)
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Introduction
The endocrine renin-angiotensin system (RAS)' is a major
focus in hypertension research. Its effector peptide angiotensin
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II (ANGII) is a potent regulator of blood pressure and electro-
lyte balance. The aspartyl protease renin cleaves angiotensino-
gen to form the decapeptide ANGI. ANGI is further hydrolized
to ANGII by angiotensin-converting enzyme.
The juxtaglomerular cells of the kidney are the major
source of plasma active renin. A low sodium concentration in
the proximal tubulus, low renal arterial pressure, noradrena-
line, and the sympathetic nerve activity are important stimula-
tors of kidney renin secretion. ANGII, high renal arterial pres-
sure and calcium influx, however, are known inhibitors of
renal renin release (for review see [1]). The dynamic interac-
tions ofblood pressure and electrolyte homeostasis with kidney
renin are thus strongly involved in many forms of hyperten-
sion.
Growing evidence for renin synthesis and for the local gen-
eration ofANGII in many extrarenal tissues ( 1-5) has recently
focused attention on the existence of autocrine or paracrine
RAS and their possible importance in primary hypertension.
However, the function, regulations, and interactions between
the plasma RAS and local paracrine RAS are far from being
understood.
The existence of an adrenal RAS had already been pro-
posed in 1967 by Ryan (6) and Ganten et al. (2, 7), who dem-
onstrated the presence of iso-renin in rat and human adrenal
gland and its stimulation by long-term sodium deficiency and
hypophysectomy. The description of modified smooth muscle
cells in the adrenal capsule with a similarity to kidney juxtaglo-
merular cells by Goormaghtigh and Handovsky (8), and the
demonstration ofrenin secretory granules by Mizuno et al. (9),
suggest the possibility of regulated secretion of adrenal renin.
Little data, however, are available for studying acute regulation
of adrenal renin release.
We have recently generated a new monogenetic model
of hypertension, the transgenic hypertensive rat TGR
(mREN2 )27 (10). The entire mouse Ren-2d renin gene is inte-
grated into their genome and they are characterized by fulmi-
nant hypertension and suppressed plasma renin concentration,
as well as high plasma prorenin levels and high tissue Ren-2d
mRNA content. The highest expression of the transgene was
found in the adrenal cortex, and the adrenal gland was demon-
strated as a major source of plasma prorenin. Furthermore,
adrenalectomy resulted in a dramatic drop in blood pressure in
TGR(mREN2)27 (10, 11). Conversely, kidney renin was
strongly suppressed. Parallel to the development of hyperten-
sion, the 24-h urinary excretions of deoxycorticosterone, corti-
costerone, 18-OH-corticosterone, and aldosterone are signifi-
cantly elevated, suggesting a role ofan intraadrenal RAS in the
regulation of adrenal steroid synthesis ( 12).
This study demonstrates that adrenal renin in TGR
(mREN2 )27 is strongly enhanced and its regulation by cAMP,
ANGII, and calcium is characterized.
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Methods
Animals. The transgenic rats TGR( mREN2)27 were housed and bred
in our laboratory (10). Heterozygous TGR(mREN2)27 were ob-
tained by cross-breeding female homozygous TGR(mREN2)27 with
male Sprague Dawley (SD) rats. SD rats were purchased from the Zen-
tralinstitut fir Versuchstierkunde, Hannover, FRG. Unless otherwise
stated, homozygous rats were treated daily with captopril 10 mg/kg
body wt in their drinking water. This was done to prevent organ dam-
age, which may modify organ function. The treatment was discontin-
ued for at least 7 d before the experiment. Animals had free access to
tap water and were fed the standard laboratory diet of Altromin®. They
were housed under alternating 12-h light and dark cycles at a constant
temperature between 20'C and 22°C.
Adrenal homogenates. Adrenals were trimmed of fat, minced,
washed three times with 0.9% NaCl, and frozen in dry ice/methanol.
They were homogenized in 0.1 M N-tris(hydroxymethyl)methyl-2-
aminoethane-sulfonic acid (TES) pH 7.2, containing 0.1 mM PMSF
and 15 mM EDTA, freeze-thawed three times, and centrifuged at
15,000 g at 4VC for 30 min. The supernatants were stored at -80'C
until analysis of renin activity was carried out. For the determination of
renin release, each adrenal was cut into eight slices, which were washed
three times in medium 199, containing 10 mM Hepes, pH 7.2, and
0.5% BSA (No. A-7906; Sigma Chemical Co., St. Louis, MO), and
incubated in I ml of fresh medium at 370C in a 5% CO2 atmosphere.
The medium was stored at -80'C until analysis.
Preparation of cell suspensions. Adult female rats weighing 200-
300 g were decapitated under ether anesthesia and the adrenals were
removed, trimmed of fat, and washed in cold medium (see above).
Adrenal cell suspensions were prepared by digesting minced adrenal
slices three times with collagenase (2 mg/ml) and DNAseI (0.2 mg/
ml) in medium 199/2% BSA per 10mM ofHepes at 37°C in a 5% CO2
atmosphere for 3 X 15 min. During each interval, the cells were dis-
persed, and undigested tissue was sedimented out. The supernatant of
the first 15 min interval was discarded, the supernatants of the second
and third incubations were kept on ice, pooled, filtered, and washed
three times with fresh medium. The cell number and viability were
determined by trypan blue exclusion in a Neubauer haemocytometer
(LHD, Heidelberg, Germany). Cell viability was between 80 and 90%
and did not decrease during the experiments. After 30 min of preincu-
bation, the medium was discarded, followed by replacement and col-
lection of the medium after the times indicated in the figure legends,
the first interval always being untreated basal release to control the
preconditions. For the determination of the intracellular renin content,
cells were washed three times after collagenase /DNAse digestion. Then
the pellet was dissolved in 0.1 M TES, pH 7.2, containing 0.1 mM
PMSF and 15 mM of EDTA, and freeze-thawed three times in dry
ice/methanol, centrifuged at 15,000 g, 4°C, for 30 min and the super-
natants stored at -80°C until analysis.
Angiotensin II amide (Hypertensin) was purchased from Ciba
(Zurich, Switzerland) and dissolved in 5 mM NaH2PO4. Final dilu-
tions were done in the incubation medium. 8-bromo-cAMP (8-Br-
cAMP) and A23187 (Sigma, (Nos. B7880 and C7522, respectively;
Sigma Chemical Co.) were dissolved in DMSO, and further diluted
with the incubation medium.
Renin determinations. Plasma was collected as EDTA plasma, ob-
tained from the retroorbital plexus after light ether anesthesia. Plasma
active and inactive renin concentrations were determined according to
a modification ofthe method described by Glorioso et al. (13). In brief,
to activate inactive renin 20 of plasma was incubated with 40 ,ul of
trypsin (400 U/ml, dissolved in TES-buffer: 0.1 M TES, pH 7.2,0.01%
neomycin, 10 mM EDTA). Samples were incubated on ice for 10 min,
and the reaction was stopped by adding 40 Ml ofsoybean trypsin inhibi-
tor (600 U/ml in TES-buffer). To determine inactive renin concentra-
tions in adrenal homogenates and incubates, the concentrations of
trypsin and soybean trypsin inhibitor were reduced to 50 U/ ml and
100 U/ ml, respectively. For the measurement of active renin, 80 Al of
TES-buffer was added without trypsin.
The pretreated samples were incubated with lyophilized renin sub-
strate isolated from nephrectomized rat plasma (final concentration:
80 mg/ml, 0.11% 2,3-dimercapto-1-propanol, 1.15 mg/ml 8-hydroxy-
chinolin in TES-buffer). The reaction was stopped with RIA buffer
(0.1 M Tris acetate, pH 7.4), (a) immediately before the incubation
and (b) 1-3 h after incubation at 370C. Generated ANGI was mea-
sured by radioimmunoassay ( 14, 15).
Specific immunoprecipitation of mouse renin. To determine the
contribution of mouse renin to the sum of mouse and rat renin, the
samples were incubated for 2 h at 40C with a monoclonal antirenin
antibody (No. 120), which we found to be specific for murine renin
with < 3% cross-reactivity to purified rat renin. The antibody was
kindly provided by Dr. Celio, Institut d'Histologie et Embryologie
generale, Universit PKrolles, Fribourg, Switzerland. The incubation
buffer was 0.1 M Tris-acetate buffer, pH 8.1. Incubation with antibody-
free buffer served as a control. Antibody/renin complexes were precipi-
tated with formalin-fixed Staphylococcus aureus protein A (Immuno-
precipitin, No. 9321 SB; Bethesda Research Laboratories, Gaithers-
burg, MD). The renin activities were determined before the procedure
and in the supernatant after immunoprecipitation.
Analysis ofRNA from adrenal cells. Cytosolic RNA was prepared
according to the method described by Wilkinson ( 16). The RNAse
protection assay was performed using 1 4g of total RNA and a mouse
Ren-2d-specific [32p] UTP-labeled antisense RNA, previously de-
scribed ( 10). A [32P] UTP-labeled antisense rat /3-actin mRNA was
used as the endogeneous control.
Results
We recently demonstrated that the major site of Ren-2d gene
expression in TGR(mREN2 )27 is the adrenal cortex ( 10, 17).
To examine the intraadrenal RAS, we addressed the question
of whether adrenal renin activity is enhanced in TGR
(mREN2 )27, due to the presence of mouse renin protein.
Fig. 1 shows renin activity with and without trypsin activa-
tion in plasma, adrenal homogenates, and supernatants ofadre-
nal slice incubations. In plasma, the active renin level is signifi-
cantly lower in TGR(mREN2)27 than in SD controls (Fig. 1
A; bar I vs. 3), while prorenin is elevated 20-fold in
TGR(mREN2)27 (Fig. 1 D; column 1 vs. 3). In adrenal ho-
mogenates both active renin and prorenin are strongly elevated
in TGR(mREN2)27 as compared with controls (Fig. 1, B and
E; bar I vs. 3).
Additionally, prorenin as well as active renin could be de-
tected in the incubate of transgenic adrenal slices, indicating
their release. Renin release from adrenal slices of SD rats was
almost undetectable. To evaluate the contribution of mouse
renin to determined renin activities, we measured the renin
activities before and after immunoprecipitation with a mono-
clonal antibody capable of specifically recognizing mouse, but
not rat, renin.
As shown in Fig. 1, the immunoprecipitation with a mouse
renin-specific antibody (No. 120) had no effect on the renin
activities measured in SD rats (Fig. 1, A-F, bar I vs. 2), but
significantly reduced renin activities in plasma, adrenal homog-
enates, and incubates ofTGR(mREN2)27 (Fig. 1, A-F, bar 3
vs. 4). In TGR( mREN2 ) 27, renin activities in adrenal homog-
enates and incubates, as well as plasma prorenin, were almost
completely blocked by the antibody to < 10% of the original
values (Fig. 1, B-F, bar 3 vs. 4).
The plasma active renin level in transgenic rats was de-
creased by about two-thirds (Fig. 1 A, bar 3 vs. 4), indicating
that the majority of plasma renin activity is derived from
mouse renin, while a significant part still represents endo-
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geneous rat renin. Thus, we have demonstrated that the adre-
nal gland of TGR(mREN2)27 contains functionally active
mouse renin derived from the Ren-2d transgene and that this
adrenal renin activity is strongly enhanced as compared with
SD rats.
To examine the pattern of renin release from adrenal cells
ofTGR(mREN2)27 in more detail and to study its regulation,
we analyzed adrenal renin secretion in vitro. While the renin
release from adrenal cell suspensions of SD rats (Table I) and
also Wistar Kyoto rats (data not shown) was below the detec-
tion limit, adrenal cells ofTGR(mREN2 )27 secreted consider-
able amounts of active renin and prorenin (Table I). Most of
the intracellular content of prorenin was released into the me-
Table I. Renin Content and Renin Release
from Adrenal Cells ofTGR(mREN2)27
+ +
F
Adrenal Supernatant
+
Renin release (ng
ANGI/h) per I mio Renin content (ng ANGI/
cells/h h) per I mio cells
Active Active
renin Prorenin renin Prorenin
Sprague Dawley -0 0 3.4±0.5 0.75±0.2
TGR(mREN2)27 1.5±0.3 6±0.75 25±3.8* 10±2.2*
Adrenal cells were prepared from adult female TGR(mREN2)27 and
from age matched SD rats. They were incubated at a concentration
of 250,000 cells/ml for a period of 90 min. * P < 0.05, TGR vs. SD;
values represent mean±SEM of four samples per group.
- Figure 1. Plasma and adrenal renin in
TGR(mREN2)27. Blood and adrenal glands were
collected from adult homozygous
TGR(mREN2)27 and from age-matched SD rats.
One adrenal gland was either homogenized in 1
ml of buffer or incubated in 1 ml of medium for a
period of 1 h. Open bars, SD; hatched bars,
TGR( mREN2)27; -, supernatant after treatment
with buffer and protein A; +, supernatant after
treatment with AB 120 and protein A. (A-C) Ac-
tive renin; (D-E) Prorenin. Mann-Whitney U test
+ for unpaired variables: n = 4; *P < 0.05; **P
<0.01.
dium after 1 h of incubation. However, only - 6% ofthe intra-
cellular content of active renin was released during the same
period of time.
To demonstrate the local synthesis of renin in adrenal cells
of TGR(mREN2)27 we next examined the effect of transla-
tion inhibition by cycloheximide. As shown in Fig. 2 B, cyclo-
heximide significantly inhibits the release ofprorenin to 20% of
that of untreated cells and the release of active renin to 65%
(Fig. 2 A). The release of renin was not affected by cyclohexi-
mide during the first 90 min of incubation. In addition, it was
more effective in inhibiting prorenin release than active renin
release.
Using this system of adrenal cell suspensions in vitro, we
were able to study the regulation of renin release from adrenal
cells ofTGR(mREN2)27. As shown in Fig. 3 A, the release of
active renin was significantly stimulated by 8-Br-cAMP for 16
h compared with unstimulated transgenic adrenal cells. The
prorenin release was significantly elevated by 8-Br-cAMP even
after 6 h ofstimulation (Fig. 3 B). This was accompanied by a
significant rise in Ren-2d mRNA as detected by a Ren2d-spe-
cific RNAse protection assay (Fig. 3 C). Thus, the release of
active renin~and prorenin from transgenic adrenal cells is stimu-
lated by 8-Br-cAMP. This is in part due to enhanced de novo
synthesis, as we conclude from the parallel increases of prore-
nin and Ren-2d mRNA under the same conditions.
We also focused on the major component of the negative
feedback loop controlling renin release from the kidney, angio-
tensin II. Our question was: does the negative feedback mecha-
nism also exist in adrenal cells ofTGR(mREN2 )27? Surpris-
744 J. Peters, K. MUnter, M. Bader, E. Hackenthal, J. J. Mullins, and D. Ganten
Plasma
4501
ial Supernatant
w --I 1
Ir E
x
-E
3(
z
Clco
c
C: 1'
a)
.t
CIO
30
SO-
C
-r--
ril 11 Im .
A
Active Renin
B
Prorenin
7.5
-
(Az
0
.2_
E
a)
a.CL,
z
4
CD
C
90 180
6.0
4.5
3.0
1.5
A
Active Renin
4-
s _*
--
Us
0
0.
(3
z
4
co
IL,
90 180
-90 0 +90 +180 B
Treatment
Figure 2. Effect of cycloheximide on renin release from adrenal cell
suspensions of TGR(mREN2)27. Cell suspensions of adrenal glands
of adult female TGR( mREN2)27 were incubated at a cell concen-
tration of 250,000 cells/ml for 90-min periods. (Open bars) Un-
treated cells; (hatched bars) cycloheximide 10 fig/ml. (A) Active
renin released; (B) prorenin released. Mann-Whitney U test for un-
paired variables and matched pairs: n = 5; *P < 0.01.
ingly, as shown in Fig. 4, ANGII has the opposite effect in
adrenal cells of TGR(mREN2)27. During 3 h of incubation,
ANGII significantly stimulates active renin release from trans-
genic adrenal cells, with a maximum three- to fourfold in-
crease, when compared with its basal release (Fig. 4 A, P
< 0.05). Importantly, with ANGII, prorenin release remained
unaffected or only slightly increased during the experiment
(Fig. 4 B, P> 0.1) . The regulation ofprorenin and active renin
release seem to be dissociated.
To date, studies on acute regulation of renin release from
adrenal cells are not available, due to the detection limit
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Figure 3. Long-term effect of 8-Br-cAMP on renin in adrenal cell
suspensions of TGR(mREN2)27. Cell suspensions of adrenal glands
of adult female TGR(mREN2)27 were incubated at a cell concen-
tration of 150,000 cells/ml. (Open bars) Transgenic control cells;
(hatched bars) transgenic cells treated with 5 mM 8-Br-cAMP. (A)
Active renin released; (B) Prorenin released; (C) Ren2d mRNA/fl-
actin mRNA after 6 h of stimulation. Mann-Whitney U test for un-
paired variables: n = 5; *P < 0.05.
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for renin activity after short incubation periods. The over-
expression of transgenic renin in adrenal glands of TGR
(mREN2)27, offers the opportunity to study those phenom-
ena in TGR(mREN2)27. The above findings suggest the exis-
tence of a regulated secretory pathway for active renin release
in adrenal cells ofTGR (mREN2)27. Therefore, we next exam-
ined the acute effects of 8-Br-cAMP, ANGII, and the calcium
ionophore A23187.
As demonstrated in Fig. 5, A-C, active renin release is signif-
icantly stimulated by all three drugs within 60 min of incuba-
tion (5 mM 8-Br-cAMP: 166±20%, P < 0.05; 1 nM ANGII:
118+±0%, P > 0.05; 10 nM ANGII: 162+20%, P < 0.05; 100
nM ANGII: 155±10%, P < 0.05; 1 pM A23187: 173±12%, P
< 0.05). The effect of ANGII was dose dependent, reaching
maximal stimulation with 10 nM ANGII. In the same experi-
ments prorenin release was not significantly affected.
Discussion
Transgenic rats TGR(mREN2)27, having integrated the
mouse Ren-2d renin gene, develop fulminant hypertension
with systolic blood pressure ranging from 200 to 280 mmHg.
We consider TGR(mREN2)27 as a model of "low plasma
renin hypertension." We further hypothesize that the overex-
pression ofthe renin gene in certain tissues results in stimulated
paracrine RAS, like in the brain, the blood vessels, the adrenal
gland, or the heart. This may then lead to hypertension develop-
ment in TGR( mREN2)27 and also to the observed downregu-
lation of kidney renin. The existence of autocrine or paracrine
RAS is supported by a number of recent findings (1, 4, 5).
Several lines of evidence indicate that hypertension in
TGR(mREN2)27 is indeed determined by the transgene activ-
ity and is not a result of insertional mutagenesis. First, in sev-
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eral independent experiments hypertensive transgenic rat
strains were generated with the same transgene integrated at
different sites. Second, the hypertension cosegregates com-
pletely with the presence ofthe transgene. Third, the hyperten-
sion responds with great sensitivity to converting enzyme inhib-
itors and ANGII antagonists. These drugs interfere with the
system to which the genetic manipulation was directed.
Fourth, mouse Ren-2d-specific transcripts were detected in the
same tissues as in Ren-2d mice, indicating correct expression of
the gene.
Here we demonstrate that the adrenal gland of TGR
(mREN2)27 contains, synthesizes, and secretes high amounts
of mouse renin originating from transcription and translation
of the transgene. Renin activity is highly increased in adrenal
cells and adrenal tissue ofTGR(mREN2)27, when compared
with SD or Wistar Kyoto rats. The inhibitory effect of cyclo-
heximide on renin release confirms that mouse renin is indeed
synthesized locally.
To demonstrate that the transgene has retained its regula-
tory properties and to gain insight into the dynamic regulation
of adrenal renin of TGR(mREN2)27, we analyzed the long-
term and short-term effects of 8-Br-cAMP, ANGII, and calci-
mycin (A23 187) on renin release from transgenic adrenal cells.
Recently, Nakamura et al. (18) and Burt et al. (19) pro-
posed a cAMP responsible element in the 5' flanking sequence
of the Ren-2d gene and demonstrated its function. However,
the stimulatory effect of cAMP on Ren-2d transcription ap-
pears to be cell-type-specific and depends on the composition
oftrans-acting factors (20). Also, an acute stimulation ofrenin
secretion by cAMP was demonstrated by several models, but
this effect is dependent on the cell type (21 ). The Ren-2d trans-
gene ofTGR(mREN2 )27 should have retained its regulatory
properties, since the fragment we used to establish this strain
contains large parts of its 5'- and 3'-flanking sequences, includ-
ing the cAMP responsible element.
Our results demonstrate that in adrenal cells of TGR
(mREN2)27, 8-Br-cAMP significantly increases the Ren-2d
mRNA content and that this is paralleled by an increased prore-
nin release 6 h after the addition of the component. Active
renin release is also enhanced by 8-Br-cAMP, but there was a
latency of several hours as compared with prorenin stimula-
tion. The effect is almost identical to the findings by Pratt et al.
(22) on human renin, Nakamaru et al. (23) on mouse Ren-2d
in AtT20 cells, and Krieger et al. (20). Since the time necessary
for packaging and maturation of storage granules is thought to
be - 16 h (24), our results suggest regulated secretion ofactive
renin from adrenal cells ofTGR(mREN2 )27.
Further results presented in this study confirm this possibil-
ity: cycloheximide only slightly suppressed active renin release
but strongly suppressed prorenin release. This effect is not pres-
ent in the first 90 min of incubation, as would be expected for
an exclusively constitutive secretion. The lack of suppression
of renin release during the first 90 min of incubation may be
due to the fact that proteins synthetized before inhibition of
translation by cycloheximide can still be released during this
incubation period. Thus the effect ofcycloheximide is masked.
In addition, we cannot completely exclude the possibility of
partial costorage of prorenin with active renin. The concept of
dissociation of prorenin and active renin secretion in the adre-
nal gland is further supported by the finding that only a small
portion ofthe active renin present intracellularly is released per
hour, while almost all ofthe cellular prorenin is released during
the same time. Furthermore, acute active renin and prorenin
release seem to be dissociated when the cells are stimulated
with 8-Br-cAMP, ANGII, or calcimycin. All three substances
stimulate active renin, but not prorenin release within 60 min
of treatment. These findings in adrenal glands of TGR
(mREN2)27 support the concept of differentially regulated
pathways of secretion for prorenin and active renin in adrenal
cells, as was described also for the kidney, mouse submandibu-
lar gland, and in AtT20 cells (21, 25-27).
The mechanisms of renin regulation and secretion in the
adrenal gland remain far from being clear. Mizuno et al. (9)
isolated renin-containing secretory granules from the rat adre-
nal cortex and demonstrated that their number is increased by
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nephrectomy, a maneuver that is known to increase the adre-
nal renin content. They, and Yamaguchi et al. (28), also sug-
gested a stimulatory long-term effect of ANGII on renin secre-
tion from rat adrenal cortical primary cell cultures. However,
due to the low abundance ofrenin in the rat adrenal cortex, the
analysis of short-term regulation is limited.
The adrenal gland was shown to be a major source of
plasma prorenin in TGR(mREN2)27, whereas the kidney
renin production is strongly suppressed ( 10, 1 1). The detection
ofhigh amounts of renin secreted from transgenic adrenal cells
confirms this finding. We therefore asked whether or not adre-
nal renin is under regulatory control similar to kidney renin.
8-Br-cAMP, which is known to stimulate renin release from
the kidney, also stimulates renin release from primary cells of
TGR(mREN2)27 adrenal glands. ANGII and increased intra-
cellular free calcium are well-known inhibitors of renal renin
release and are important in negative feedback regulations of
blood pressure ( 1). Both factors do not suppress adrenal renin
release in TGR( mREN2 )27 but instead significantly stimulate
active renin release eliciting a quick response. Since ANGII is
known to elevate intracellular free calcium, the effect ofANGII
may be mediated via calcium.
The stimulatory effect of ANGII on active renin release
may be an epiphenomenon of the transgenic model but could
also represent an endogeneous mechanism. The findings of
Mizuno et al. and Yamaguchi et al. (9, 28) speak in favor ofthe
second possibility. Most likely, the specific apparatus ofthe cell
type (e.g., endocrine cells, juxtaglomerular cells, submandibu-
lar gland cells) define in part the pattern of renin regulation. In
any case, the positive feedback loop between renin release and
ANGII may be important for the regulation of adrenal steroid
metabolism, plasma renin, and in the pathophysiology of hy-
pertension, at least in TGR(mREN2)27. This remains to be
investigated.
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